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Autophagy is an important intracellular catabolic
mechanism that mediates the degradation of cyto-
plasmic proteins and organelles. We report a
potent small molecule inhibitor of autophagy named
‘‘spautin-1’’ for specific and potent autophagy inhib-
itor-1. Spautin-1 promotes the degradation of Vps34
PI3 kinase complexes by inhibiting two ubiquitin-
specific peptidases, USP10 and USP13, that target
the Beclin1 subunit of Vps34 complexes. Beclin1 is
a tumor suppressor and frequently monoallelically
lost in human cancers. Interestingly, Beclin1 also
controls the protein stabilities of USP10 and USP13
by regulating their deubiquitinating activities. Since
USP10 mediates the deubiquitination of p53, regu-
lating deubiquitination activity of USP10 and USP13
by Beclin1 provides a mechanism for Beclin1 to
control the levels of p53. Our study provides amolec-
ular mechanism involving protein deubiquitination
that connects two important tumor suppressors,
p53 and Beclin1, and a potent small molecule inhib-
itor of autophagy as a possible lead compound for
developing anticancer drugs.
INTRODUCTION
Vps34 is the primordial member of the PI3 kinase family and the
only known class III PI3 kinase that can phosphorylate the D-3
position on the inositol ring of phosphatidylinositol (PtdIns) to
produce PtdIns3P (Schu et al., 1993). In contrast to class I PI3
kinase, which has been extensively studied, much less is known
about the class III PI3 kinase or its regulation in mammalian cells.
Emerging evidence indicates a central role of Vps34 PI3K activity
and its protein partners in orchestrating both initiation and matu-ration of autophagosomes (Simonsen and Tooze, 2009). Thus,
exploring the mechanisms that regulate the class III PI3 kinase
has direct implications in our understanding of these important
intracellular mechanisms as well as for developing therapies
for treatment of human diseases.
Similar to their homologs in yeast, Vps34 in mammalian cells is
present in two complexes: Vps34 complex I and Vps34 complex
II (Itakura et al., 2008; Liang et al., 2006; Matsunaga et al., 2009;
Zhong et al., 2009). These two complexes share the core compo-
nents of Vps34, Beclin1 and p150; and in addition, complex I
contains Atg14L and complex II contains UVRAG. Interestingly,
the stabilities of different components of Vps34 complexes are
codependent upon each other as knockdown of one component
often reduces the levels of others in the complexes (Itakura et al.,
2008).
Beclin1 has been characterized as a tumor suppressor, and its
importance is underscored by both the frequent monoallelic loss
of beclin1 in human breast, ovarian and prostate tumors, and
an increased rate of malignant tumors in BECN1+/mice (Liang
et al., 1999; Qu et al., 2003; Yue et al., 2003). Although autophagy
deficiency has been proposed to be the mechanism for the
increased tumorigenesis in BECN1+/ mice, a recent study
using tissue-specific knockout mice of Atg5 and Atg7 suggests
that autophagy deficiency may lead to benign tumors in livers,
but not in other tissues (Takamura et al., 2011). Thus, the mech-
anism of Beclin1 as a tumor suppressor remains as a puzzle.
Small molecule inhibitors are important tools in exploring the
cellular mechanisms in mammalian cells. However, the only
available small molecule inhibitor of autophagy is 3-methylade-
nine (3-MA), which has a working concentration of 10 mM
and inhibits multiple forms of PI3 kinases. Therefore, there is
an urgent need to develop highly specific small molecule tools
that can be used to facilitate the studies of autophagy in
mammalian cells. Using an imaging-based screen, we identified
a small molecule inhibitor of autophagy and developed it into
a highly potent autophagy inhibitor. We named it ‘‘spautin-1’’
for specific and potent autophagy inhibitor-1. We explored theCell 147, 223–234, September 30, 2011 ª2011 Elsevier Inc. 223
Figure 1. Isolation of a Series of Small Molecule Inhibitors of Autophagy
(A) The structure of MBCQ.
(B) MBCQ reduced the spot numbers (a), spot size (b), and spot intensity (c) of LC3-GFP+ puncta. H4-LC3-GFP cells were treated with rapamycin (0.2 mM) and
MBCQ (5 mM) as indicated. The image data are expressed as % of control vehicle treated cells. 1000 cells were analyzed per treatment condition.
(C) H4-LC3-GFP cells were treated with rapamycin (0.2 mM) and MBCQ (10 mM) as indicated for 2 hr and the cell lysates were analyzed by western blotting using
anti-LC3. b-tubulin was used as a control.
(D) An active (C43=spautin-1) and an inactive (C71) derivatives of MBCQ.
(E) MEF cells were treated with DMSO (1&), rapamycin (0.2 mM) alone, or together with MBCQ (10 mM), C43 (10 mM) or C71 (10 mM) for 4 hr. The cell lysates were
analyzed for western blotting using anti-LC3 antibody. b-tubulin was used as a loading control.
(F) Dose-response (in mM) of C43 and inactive C71. H4-LC3-GFP cells were treated with rapamycin (0.2 mM) for 12 hr with C43 or C71 as indicated. The LC3-GFP+
puncta were quantified as in (B). Autophagy index = % {[total LC3-GFP+ spot intensity (compound+rapamycin treated) per cell] – [total LC3-GFP+ spot intensity
(DMSO treated) per cell]} / {[total LC3-GFP+ spot intensity (rapamycin treated) per cell] – [total LC3-GFP+ spot intensity (DMSO treated) per cell]}. Rap =
rapamycin.
(G) H4-LC3-GFP cells were treated with spautin-1(10 mM) with or without E64D (5 mM) for indicated periods of time. The cell lysates were analyzed by western
blotting using anti-LC3 and anti-b-tubulin.
All error bars indicate STD. See also Figure S1 and S2.mechanism by which spautin-1 inhibits autophagy and found
that it inhibits two ubiquitin specific peptidases, USP10 and
USP13, which regulate the deubiquitination of Beclin1 in Vps34
complexes. Using spautin-1 as a tool, we explored the interac-
tion of USP10 and USP13 with Vps34 complexes. Interestingly,
we found that Vps34 complexes interact with USP13 and the
stabilities of USP10 and USP13 are coordinately regulated with
that of Vps34 complexes. Since USP10 is a deubiquitinating
enzyme for p53 and regulates the levels of p53 by controlling
p53 ubiquitination and degradation (Yuan et al., 2010), regulating
the stability of USP10 and USP13 by Vps34 complexes provides
a molecular mechanism for class III PI3 kinase to control the
levels of p53. Indeed, as predicted by our model, we found
that the levels of p53 are reduced in the tissues of BECN1+/224 Cell 147, 223–234, September 30, 2011 ª2011 Elsevier Inc.mice, which provide a molecular mechanism for the increased
tumorigenesis after monoallelic loss of beclin1. Our results
demonstrate that class III PI3 kinase is an important tumor
suppressor that can regulate the levels of p53 through controlling
its deubiquitination.
RESULTS
Isolation of a Small Molecule Inhibitor of Autophagy
by an Image-Based Screen
In an imaging-based screen using LC3-GFP as a marker for
autophagy (Zhang et al., 2007), we identified a small molecule
inhibitor of autophagy, MBCQ, from the ICCB known bioactive
library (Figure 1A). MBCQ was previously known as an inhibitor
of phosphodiesterase type 5 (PDE5), an enzyme that degrades
cGMP by hydrolysis (MacPherson et al., 2006). Stimulation of
H4-LC3-GFP cells with rapamycin led to increases in the levels
of LC3-GFP as expected. A quantitative analysis of LC3-GFP
puncta using high throughput microscopy showed that the treat-
ment of MBCQ reduced the spot numbers as well as spot size
and spot intensity of LC3-GFP dots compared to that of control
or rapamycin treatment alone (Figure 1B). Thus, the presence of
MBCQ inhibited both basal as well as rapamycin induced LC3-
GFP autophagic puncta.
This result was further confirmed by LC3 western blot analysis
(Figure 1C), and similar results were obtained using mouse
embryonic fibroblast cells (MEFs) (Figure S1A). Inhibition of
autophagy byMBCQwas rapid (Figure 1B) and dose-dependent
with an IC50 of 0.8 mM (Figure S1B), which is significantly more
potent than the commonly used class III PI3 kinase inhibitor,
3-methyladenine (3-MA). We have also confirmed the autophagy
inhibitory activity of MBCQ by electron microscopic studies.
Cells treated with rapamycin showed a large number of autopha-
gosomes with characteristic double membrane, which were
conspicuously absent in cells treated with rapamycin and
MBCQ (Figure S1C). Finally, the treatment of MBCQ was able
to reduce the autophagic puncta of LC3-GFP in the presence
of rapamycin, under starvation conditions or with bafilomycin
which blocks lysosomal degradation (Figure S1D). Thus,
MBCQ is an upstream inhibitor of autophagy.
Autophagy-Inhibiting Activity of MBCQ Can Be
Separated from Its PDE5-Inhibiting Activity
One hundred and twelve derivatives of MBCQ were synthesized
and analyzed to determine if its activity in inhibiting autophagy
could be separated from its inhibition of PDE5 (Table S1 and
data not shown). The chemical synthetic schemes are shown
in the Extended Experimental Procedures. We selected 9
MBCQderivatives based on their efficacy in inhibiting autophagy
and screened for their activities on PDE5 (Wang et al., 2008). We
found that C43 (6-fluoro-N-[4-fluorobenzyl]quinazolin-4-amine),
an effective autophagy inhibitor with an IC50 of 0.74 mM (Fig-
ure 1D-F), which is comparable to that of MBCQ, has signifi-
cantly reduced activity toward PDE5 and other PDEs (Figures
S2A and S2B and Table S1). Thus, the PDE5 inhibiting activity
of MBCQ can be chemically separated from its autophagy inhib-
iting activity.
Consistent with a separation of PDE5 and autophagy inhibiting
activities in MBCQ, there were a number of other known PDE5
inhibitors in the bioactive library that we screened, including
MY-5445, dipyridamole, IBMX and sildenafil (Viagra), which
were not identified as autophagy inhibitors. To further confirm
this conclusion, we treated H4-LC3-GFP cells with rapamycin
and other PDE5 inhibitors including MY-5445, dipyridamole,
IBMX or sildenafil using MBCQ as a positive control. None of
the specific PDE5 inhibitors tested, including the most potent
PDE5 inhibitor, sildenafil (Viagra) which has an IC50 of 2.5 nM
for PDE5, had any activity on autophagy (data not shown).
Thus, we conclude that the autophagy inhibiting activity of
MBCQ is not related to its PDE5 inhibiting activity.
To further examine the specificity of C43 in inhibiting auto-
phagy, we treated mouse embryo fibroblasts (MEF) cells withC43 or C71, a negative control, in the presence of rapamycin
with the levels of autophagy determined by LC3western blotting.
Treatment with C43, but not a negative control C71, inhibited
autophagy induced by rapamycin (Figures 1D–1F) and starvation
(Figure S2C). We also confirmed the inhibition of autophagy by
C43 using electron microscopy (Figure S2D). Furthermore, the
treatment of C43 inhibited autophagy activated in the presence
of E64D, a protease inhibitor that increases the accumulation
of autophagosome by blocking lysosomal degradation (Fig-
ure 1G). Based on these data, we conclude that C43 is a potent
inhibitor of autophagy and named it ‘‘spautin-1’’ for specific and
potent autophagy inhibitor-1.
Spautin-1 Promotes Cell Death under Starvation
Condition and Inhibits Autophagic Cell Death
We first characterized the biological effects of spautin-1 at the
cellular level in a selected subset of cancer cell lines. Spautin-1
had no effect on the growth and survival of Bcap-37 cells under
normal culture conditions (Figure 2A) but dramatically enhanced
cell death in glucose-free media (Figure 2B). Bcap-37 cells
treated with spautin-1 under glucose-free condition showed
apoptotic morphology (Figure 2C) and characteristic PARP
cleavage (Figure 2D). Western blotting for LC3 further confirmed
that autophagy was induced under glucose-free conditions,
which was inhibited by spautin-1 (Figure 2E). Similar results
were obtained with MCF-7 and BT549 cells (data not shown).
Thus, spautin-1 can sensitize tumor cells to apoptosis under
nutritional deprived conditions.
In contrast to the above cancer cell lines analyzed, MDCK
cells, a normal cell line derived from the Madin-Darby canine
kidney, treatment with spautin-1 under glucose-free conditions
did not undergo apoptosis (Figures S3A and S3B). Hs578Bst
cells, a myoepithelial cell line established from normal tissue
peripheral to a breast cancer, were also not sensitive to the treat-
ment of spautin-1 (Figures S3C and S3D). These results are
consistent with the proposal that cancer cells are under
increased metabolic pressure and therefore more sensitive to
inhibition of autophagy than that of normal cells (Karantza-
Wadsworth et al., 2007).
Increased activation of autophagy in apoptosis deficient cells
has been shown to mediate cell death (Shimizu et al., 2004). To
test this possibility, we treated Bax/Bak double knockout (DKO)
cells with etoposide to induce cell death by DNA damage in the
presence or absence of spautin-1. We found that spautin-1
inhibited etoposide induced autophagic cell death of Bax-Bak
DKO cells (Figures S3E–S3G). Thus, spautin-1 can be used
as a tool to explore the requirement of autophagy in cellular
processes.
Spautin-1 Selectively Promotes the Degradation
of Vps34 Complexes
To explore the mechanism by which spautin-1 inhibits auto-
phagy, we first examined the effects of spautin-1 on FYVE-
RFP, an indicator for the activity of class III PI3 kinase, because
PtdIns3P, the product of class III PI3 kinase, is important for the
formation of autophagosomes (Gaullier et al., 1998; Simonsen
and Tooze, 2009). Treatment with spautin-1 (Figure 3A) and
MBCQ (Figure S4A) reduced the levels of FYVE-RFP puncta,Cell 147, 223–234, September 30, 2011 ª2011 Elsevier Inc. 225
Figure 2. The Biological Effects of Spautin-1 on Cellular Models of Cell Death
Bcap-37 cells were treated with indicated compounds in normal DMEM with 10% bovine serum (A), glucose free condition (B) or both (C-E) for 48 hr. The cell
viability was determined by MTT assay (A), (B), imaged using a phase contrast microscope (C) or the cell lysates were analyzed by western blotting using anti-
PARP (D), anti-LC3 and anti-b-tubulin (as a control) (E). All error bars indicate STD. See also Figure S3.but had no effect on the protein levels of FYVE-RFP (Figure S4B),
suggesting that spautin-1 reduced the levels of PtdIns3P. The
reduction of PtdIns3P in spautin-1 treated cells was confirmed
using lipid dot blot analysis (Gozani et al., 2003)(Figure 3B).
However, spautin-1 does not inhibit the lipid kinase activity of
Vps34 in vitro (data not shown). Thus, spautin-1 can reduce
the levels of PtdIns3P in cells, but is not a direct inhibitor of class
III PI3 kinase activity.
Interestingly, we noted that the levels of Flag-Beclin1 and
HA-Vps34 were considerably lower in spautin-1 treated cells
than that of control cells (Figure 3C). In addition, treatment with
spautin-1 also reduced the levels of GFP-p150 and Myc-
Atg14L (Figures 3D and 3E). On the other hand, the treatment
of spautin-1 had no effect on the protein levels of GFP alone,
GFP-Arf1, GFP-MT, EGFR, HA-Hrs, HA-Atg3, or GFP-Atg7
(data not shown). Thus, spautin-1 selectively reduces the levels
of exogenously expressed components of Vps34 complexes.
To determine if spautin-1 has a similar effect on endogenous
Vps34 complexes, we conducted a time course study of H4-
LC3-GFP cells treated with spautin-1 by western blotting. We
found that the levels of endogenous Beclin1, Vps34, p150,
Atg14L, and UVRAG progressively decreased in a time-depen-
dent manner in the presence of spautin-1, and the effect of spau-
tin-1 on the levels of Vps34 complexes was strongly correlated
with that of LC3II (Figure 3F). Other active derivatives such as
MBCQ have similar activity profiles (data not shown). In contrast,
the treatment of 3-MA has no effect on the protein level of
Beclin1 (Figure S4C). These data confirm that spautin-1 selec-
tively reduces the levels of Vps34 complexes inmammalian cells.
To explore the mechanism by which spautin-1 reduces the
levels of Vps34 complexes, we treated H4-LC3-GFP cells with
MBCQ or spautin-1 in the presence or absence of CHX. As
shown in Figure 3G, the addition of spautin-1 with CHX reduced
the levels of Beclin1 and Vps34 compared to that of CHX alone,
suggesting that spautin-1 may promote the degradation of the
class III PI3 kinase complexes. To further examine this possi-226 Cell 147, 223–234, September 30, 2011 ª2011 Elsevier Inc.bility, we treated H4-LC3-GFP cells with spautin-1 in the pres-
ence of MG132 or NH4Cl to inhibit proteasomal or lysosomal
degradation, respectively. MG132 but not NH4Cl inhibited the
reduction of Beclin1 induced by spautin-1 (Figure 3H). The addi-
tion of MG132 restored the levels of Vps34 complexes as well
as that of autophagy (Figure S5A). Similar results were found
with transfected GFP-Beclin1 in 293T cells (Figure S5B). These
results suggest that spautin-1 promotes the degradation of
Beclin1 through the proteasomal pathway. Since ubiquitination
represents an essential step in mediating proteasomal degrada-
tion, we tested if ubiquitination of Beclin1 was increased in
cells treated with spautin-1. As shown in Figure 3I, the treatment
of spautin-1 promoted the ubiquitination of Beclin1 without an
obvious effect on the global levels of ubiquitination. Taken
together, we conclude that spautin-1 inhibits autophagy by
selectively promoting the degradation of the class III PI3 kinase
complexes via the proteasomal pathway.
Identification of the Deubiquitinating Enzymes
for Vps34 Complexes
Since ubiquitination of proteins plays a critical role in mediating
proteasomal degradation, we hypothesize that spautin-1 targets
deubiquitinating enzyme(s) (DUBs) which normally function to
negatively regulate the ubiquitination of Vps34 complexes. This
follows from the common finding that a small molecule is more
likely to be an inhibitor than an activator. To directly test this
hypothesis, we screened a collection of 127 siRNAs targeting
Human Deubiquitinating Enzymes from the Dharmacon library
SMART pools for inhibition of autophagy using H4-LC3-GFP
cells as an assay. We found that only knockdown of USP10 or
USP13 showed a consistent effect of reducing the levels of
endogenous Vps34, Beclin1, Atg14L, p150 and UVRAG (Figures
4A and 4B). Interestingly, the treatment of spautin-1 also
reduced the levels of USP10 and USP13, but not USP14,
a DUB involved in regulating proteasome function (Lee et al.,
2010), or Rubicon, a negative regulator of type III PI3 kinase
Figure 3. Spautin-1 Reduces the Levels of PtdIns3P by Promoting the Degradation of Vps34 Complexes
(A) H4-FYVE-RFP cells were treated with rapamycin (0.2 mM) and/or spautin-1 (10 mM) as indicated. The image data are expressed as% of control vehicle treated
cells. 1000 cells were analyzed per treatment condition. Rap = rapamycin.
(B) MEF cells were treatedwith DMSO (1&), rapamycin (0.2 mM), spautin-1 (10 mM) as indicated for 4 hr. The lipids were extracted and applied onto polyvinylidene
fluoride membrane. The commercial PtdIns3P was spotted as indicated for controls. The levels of PtdIns3P were detected using GST-PX-p40 domain protein,
which binds to PtdIns3P, and anti-GST antibody (top panel). The levels of PtdIns4P, detected using GST-PH-FAPP-1 domain protein which binds to PtdIns4P,
and anti-GST antibody, were used as a loading control (bottom panel).
(C-E) 293T cells were transfected with expression vectors of HA-Vps34 and Flag-Beclin 1 (C), GFP-p150 (D), or myc-Atg14L (E). Twenty-four hours after
transfection, cells were treated with DMSO (1&), MBCQ (10 mM) or spautin-1 (10 mM) as indicated for 24 hr. The cell lysates were analyzed by western blotting
using anti-HA, anti-Flag, anti-GFP, anti-myc as indicated or anti-b-tubulin (as a control).
(F) H4-LC3-GFP cells were treated with spautin-1 (10 mM) as indicated, the cell lysates were analyzed by western blotting using indicated antibodies. b-tubulin
was used as a control.
(G) H4-LC3-GFP cells were treated with CHX (10 mM) or spautin-1 at indicated concentrations for 12 hr. DMSO (1&) was used as a negative control. The cell
lysates were analyzed by western blotting using anti-Beclin1, anti-Vps34, or anti-b-tubulin (as a control).
(H) H4-LC3-GFP cells were incubated with MG132 (10 mM) or NH4Cl (10 mM) with or without spautin-1 (10 mM) for 6 hr. The cell lysates were analyzed by western
blotting using using indicated antibodies. b-tubulin was used as a control.
(I) 293T cells were transfectedwith GFP-Beclin1 andHA-Ub expression vectors. Twenty-four hours after transfection, cells were treatedwith spautin-1 (10 mM) for
24 hr and MG132 (5 mM) was added in the last 6 hr. The cell lysates were immunoprecipitated with anti-GFP antibody and the immunocomplexes were analyzed
by western blotting using anti-HA antibody. All error bars indicate STD. See also Figure S4.(Matsunaga et al., 2009; Zhong et al., 2009) (Figure 4C). Similarly,
the treatment of MEF cells with spautin-1 also led to a time-
dependent reduction in the levels of USP10, USP13, Vps34
complexes and autophagy (Figure S5C). In addition, we
compared the effects of spautin-1 on HeLa and Bcap-37 cells
under normal culture condition and autophagy induction condi-
tions (Figures S5D and S5E). Interestingly, we found that the
reduction in the levels of Vps34 complexes in Bcap-37 cells
was significantly stronger under autophagy induction conditions
than that under normal culture conditions, where autophagy
levels are low.
Because the reductions in the levels of USP10 and USP13 in
H4-LC3-GFP cells treated with spautin-1 appeared later than
the reductions in the levels of Vps34 complexes and autophagy
(Figure 4C), the reduced levels of USP10 and USP13 are unlikelyto be the primary reason for the ability of spautin-1 to reduce the
levels of PtdIns3P and inhibit autophagy. Since the treatment
with spautin-1 increases the ubiquitination levels of Beclin1
and knockdown of USP10 or USP13 reduces the levels of
Vps34 complexes, we considered the possibility that spautin-1
targets USP10 and USP13 mediated the deubiquitination of
Vps34 complexes. We first examined the ability of USP10 and
USP13 to mediate the deubiquitination of Vps34 complexes.
We found that the overexpression of USP10 was highly effective
in reducing the levels of ubiquitinated Beclin1, and this effect
was inhibited in the presence of spautin-1 (Figure 4D). Similarly,
the overexpression of USP13 reduced the levels of ubiquitinated
Beclin1 which was inhibited by spautin-1 (Figure 4E). On the
other hand, overexpression of USP10 or USP13 had no obvious
effects on the ubiquitination levels of overexpressed Vps34,Cell 147, 223–234, September 30, 2011 ª2011 Elsevier Inc. 227
Figure 4. Spautin-1 Inhibits the Deubiquitination of Vps34 Complexes
(A) and (B) H4-LC3-GFP cells were transfected with indicated siRNAs for 72 hr or treated with rapamycin (0.25 mM) or spautin-1 (10 mM) as indicated, the cell
lysates were analyzed by western blotting using indicated antibodies. b-tubulin was used as a control.
(C) H4-LC3-GFP cells were treated with spautin-1 (10 mM) as indicated, the cell lysates were analyzed by western blotting using indicated antibodies. b-tubulin
was used as a control.
(D and E) 293T cells were transfectedwith indicated expression vectors for 12 hr, incubated withMG132 (10 mM), with or without spautin-1 (10 mM) for 4 hr, the cell
lysates were immunoprecipitated with anti-Beclin1 and the immunocomplexes were analyzed by western blotting using anti-HA antibody.
(F) and (G) Ubiquitinated Beclin1 was incubated with immunopurified Flag-USP10, Myc-USP13, or Flag-USP10CA, with or without spautin-1 for 2 hr in vitro in
deubiquitinating buffer. The western blot was blotted with anti-Beclin1 antibody.
(H) and (I) Proteins indicated purified from 293T cells and different concentrations of spautin-1 (20 mM to 100 nM) were mixed and incubated for 30 min. Ub-AMC
was then added to each well and incubated for another 45 min. The final concentrations of every protein and Ub–AMC were 20 nM and 0.8 mM, respectively.
Ub–AMC hydrolysis was measured.
All error bars indicate STD. See also Figure S5.Atg14L, p150, and UVRAG (Figures S6A–S6H). Taken together,
these results suggest that Beclin1 is the primary target of
USP10 and USP13.
To directly test if spautin-1 can inhibit the deubiquitinating
activity of USP10 and USP13, we tested the activity of isolated
USP10 and USP13 on ubiquitinated Beclin1 in vitro. As shown
in Figures 4F and 4G, the coincubation of ubiquitinated Beclin1
with USP10 or USP13 but not a catalytically inactive USP10
mutant reduced the levels of Beclin1 ubiquitination. Further-
more, the presence of spautin-1 inhibited the deubiquitination
of Beclin1 mediated by USP10 and USP13. In contrast, spau-
tin-1 had no effect on CYLD-mediated deubiquitination of RIP1
in vitro (data not shown). To further confirm this result, we devel-
oped an in vitro deubiquitination assay using Ub-AMC (the
C-terminal derivatization of ubiquitin with 7-amino-4-methylcou-
marin), which is a fluorogenic substrate for deubiquitinating228 Cell 147, 223–234, September 30, 2011 ª2011 Elsevier Inc.enzymes (DUBs) (Dang et al., 1998). Using this assay, we found
that spautin-1 inhibited USP10 and USP13 with IC50 of 0.6-
0.7 mM while having no inhibitory activity toward CYLD which
is also a member of ubiquitin specific peptidase family (Figures
4H and 4I). Thus, spautin-1 is an inhibitor of the deubiquitinating
activity of USP10 and USP13. Our results suggest that inhibition
of USP10 and USP13 by spautin-1 promotes the ubiquitination
and degradation of Vps34 complexes which in turn leads to
a reduction in the levels of PtdIns3P and consequent inhibition
of autophagy.
Regulation of USP10 and USP13 by Vps34 Complexes
Unexpectedly, we found that the knockdown of Beclin1 or Vps34
could also reduce the endogenous levels of USP10 and USP13
(Figures 5A and 5B). This suggests that Vps34 complexes may
be able to regulate their own levels by stabilizing their cognate
Figure 5. Regulation of USP13 by Vps34 Complexes
(A andB) H4-LC3-GFP cells were transfectedwith indicated siRNAs for 72 hr or treatedwith rapamycin (0.25 mM) or spautin-1 (10 mM) for 4 hr, the cell lysateswere
analyzed by western blotting using indicated antibodies. b-tubulin was used as a control.
(C) H4-LC3-GFP cells were treated with MG132 (10 mM) and spautin-1 (10 mM) for 6 hr. The cell lysates were immunoprecipitated with anti-USP13 antibody and
the immunocomplexes were analyzed by western blotting using anti-Beclin1 antibody.
(D) A schematic diagram of Beclin1 truncation mutants used in (E).
(E) 293T cells were transfected withMyc-USP13, Flag-Beclin1, Flag-Beclin1-DC-term, Flag-Beclin1-DBD, Flag-Belin1-DBD,CCD,CED as indicated for 24 hr. The
cell lysates were immunoprecipitated with anti-flag antibody and the immunocomplexes were analyzed by western blotting using anti-USP13 antibody.
(F and G) 293T cells were transfected with flag-Beclin1 or flag-DC-Beclin1 for 24 hr, and then treated with spautin-1(10 mM) as indicated. The cell lysates were
assayed by anti-flag, anti-Vps34, anti-p53, anti-LC3, b-tubulin (loading control) as indicated.
(H) Flag-Beclin1, Flag-USP10 and Myc-USP13 proteins were isolated from 293T cells individually transfected with the relevant expression constructs by
immunoprecipitation followed by extensive washing (12x) and elution with tag peptides. Deubiquitinating activities of indicated proteins were analyzed using
Ub-AMC assay. Line 1: Myc-USP13, Flag-USP10 and Flag-Beclin1; Line 2: Myc-USP13 and Flag-Beclin1; Line 3: Flag-USP10 and Flag-Beclin1; Line 4: Myc-
USP13 and Flag-USP10; Line 5: Myc-USP13; Line 6: Flag-USP10; Line 7: Flag-Beclin1.
(I) 293T cells were transfected with indicated expression vectors for 12 hr, incubated with MG132 (10 mM) in the presence or absence of spautin-1 (10 mM) for
an additional 4 hr. The cell lysates were immunoprecipitated with anti-USP10 antibody and the immunocomplexes were analyzed by western blotting using
anti-HA antibody.
See also Figure S6.deubiquitinating enzymes including USP10 and USP13. This
effect is not likely mediated through PtdIns3P, the product of
Vps34 complexes, as the treatment of 3-MA which inhibits the
kinase activity of class III PI3 kinase had no effect on the levels
of USP10 or USP13 (data not shown). Thus, Vps34 complexes
have the surprising role of regulating the stability of USP10 and
USP13.
To determine the mechanism by which Vps34 complexes
regulate the stability of USP13 and USP10, we examined the
possibility that Beclin1 may interact with USP10 and USP13.We found that endogenous Beclin1 can interact with USP13
and the interaction was reduced in the presence of spautin-1
(Figure 5C). However, the interaction of Beclin1 and USP10
was considerably weaker (data not shown). These data suggest
that Beclin1 may closely interact with USP13, whereas its inter-
action with USP10 is indirect or transient in nature.
To further characterize the interaction of USP13 with Beclin1,
we determined the domains of Beclin1 that interact with USP13
(Figure 5D & E). Different truncation mutants of Beclin1 were
coexpressed with USP13 in 293T cells and the interaction ofCell 147, 223–234, September 30, 2011 ª2011 Elsevier Inc. 229
USP13 with different Beclin1 mutants was analyzed by coimmu-
noprecipitation. A C-terminal deletion mutant of Beclin1 (DC-
Beclin1) showed significantly reduced binding with USP13,
suggesting the C terminus of Beclin1 is important for the interac-
tion. We further compared the effect of spautin-1 in 293T cells ex-
pressing DC-Beclin1 mutant or full length Beclin1 (Figures 5F and
5G). Interestingly, we found that not only was the DC-Beclin1
mutant resistant to spautin-induced degradation, but the expres-
sion of DC-Beclin1 mutant significantly blocked the effect of
spautin-1 in inhibiting autophagy and inducing the degradation
of Vps34. Since DC-Beclin1 can bind to Vps34 (Furuya et al.,
2010) but not USP13, this experiment suggests that the interac-
tion of Beclin1 and USP13 is critically important for regulating the
stability of Vps34 complexes in response to spautin-1 treatment.
To directly examine the mechanism by which Beclin1 regu-
lates USP10 and USP13, we determined the effects of their inter-
action on the deubiquitinating activities in vitro using Ub-AMC as
a substrate. As shown in Figure 5H, the DUB activities of USP10
or USP13 were comparatively low when incubated alone with
Ub-AMC. Interestingly, the DUB activities were significantly
increased when USP13 and USP10 coincubated together or
with Beclin1 or all 3 proteins together, suggesting the DUB
activity can be significantly enhanced when USP13 interacts
with its substrate Beclin1 or USP10. Thus, reduced levels of
USP10 and USP13 in the presence of spautin-1 or with beclin1
knockdown may be due to their increased ubiquitination and
degradation through the proteasome pathway. Consistent with
this possibility, the effect of spautin-1 on the levels of USP10
and Vps34 complexes can be fully restored in the presence of
MG132 (Figure S5A). Furthermore, the effect of Beclin1 knock-
down on reduced levels of USP10 and USP13 can also be
inhibited by MG132 (Figure S7B).
Deubiqutination of USP10 by USP13
Since the treatment of spautin-1 also led to reduced levels of
USP10, which was inhibited by the addition of MG132 (Fig-
ure S5A), it is likely that the levels of USP10 and USP13 are
also regulated by ubiquitination. Interestingly, knockdown of
either USP10 or USP13 led to reductions in the levels of the other
(Figures 4A and 4B). Thus, we considered the possibility that
USP10 and USP13 may regulate deubiquitination of each other.
Consistent with this possibility, the ubiquitination levels of
USP10 were reduced when cells were cotransfected with an
expression vector of USP13 and the addition of spautin-1 in-
hibited the deubiquitination of USP10 by USP13 (Figure 5I). On
the other hand, coexpression of USP10 with USP13 has a
much less pronounced effect on ubiquitination of USP13 (data
not shown). These results suggest that USP13 may directly
regulate the deubiquitination of USP10; however, USP10 may
regulate USP13 indirectly perhaps by affecting the levels of
Vps34 complexes. Since USP10 mediates the deubiquitination
of Beclin1 and reduced levels of USP10 leads to increased ubiq-
uitination and degradation of Vps34 complexes, reduced levels
of Vps34 complexes as a result of USP10 reduction may in
turn lead to destabilization of USP13.
Our data supports an interactive regulatory relationship of
USP10 and USP13 with Vps34 complexes. We propose that
USP10 and USP13 mediate the deubiqutination of Vps34230 Cell 147, 223–234, September 30, 2011 ª2011 Elsevier Inc.complexes to regulate the levels of class III PI3 kinase. Further-
more, Beclin1 also interacts with USP13 and regulates the
stability of USP13. Since USP13 can also deubiquitinate
USP10, regulating the stability of USP13 by Beclin1 provides a
mechanism for Beclin1 to control the stability of USP10. Thus,
our data suggest that the levels of Vps34 complexes may be
coupled to the levels of USP10 and USP13.
Regulation of p53 via Vps34 Complexes
and Deubiquitination
Since USP10 is known as a deubiquitinating protease of p53
(Yuan et al., 2010), inhibition of USP10 by spautin-1 may
promote the degradation of p53. Consistent with this possibility,
the treatment of spautin-1 led to a reduction in the levels of p53
that was inhibited in the presence of MG132 (Figure S5A).
Furthermore, spautin-1 induced reduction in the levels of p53
was inhibited with knockdown of MDM2, the major E3 ubiquitin
ligase for p53 (Figure 6A). On the other hand, knockdown of
Mdm2 had no effect on spautin-1 induced reduction of USP10,
USP13, Vps34 or Beclin1. In addition, we found that knockdown
of USP10, USP13, Beclin1, Vps34, p150, UVRAG, Atg14L all led
to reduction in the levels of p53 (Figures 6B–6E; Figure S7A).
Thus, the cellular levels of p53 may be coordinately regulated
with that of Vps34 complexes via deubiquitinating enzymes
such as USP10 and USP13. Finally, consistent with Beclin1
being the primary target of USP10 and USP13, the expression
of DC Beclin1, which behaves as a dominant negative in inhibit-
ing the loss of Vps34 complexes and autophagy, also inhibited
the reduction of p53 induced by spautin-1 (Figure 5F and 5G).
Since our model predicts that the levels of class III PI3 kinase
should be correlated with that of p53, we examined the levels of
p53 in BECN1+/ mice. As shown in Figure 6F, the levels
of Beclin1 in newborn BECN1+/ mice are approximately half
of that in wt mice. Consistent with a coordinated regulation of
Vps34 complex components, the levels of Vps34, Atg14L,
p150 and UVRAG are also significantly reduced in BECN1+/
tissues. Interestingly, as predicted by our model, the levels of
USP10 and p53 in the heart, lung and liver of newborn
BECN1+/ mice are correspondingly reduced. The levels of
USP13 could not be examined currently due to a lack of antibody
that can recognize murine USP13. The levels of LC3II in
BECN1+/ liver are reduced compared to that of wt. On the
other hand, the reduction of LC3II in heart and lung of
BECN1+/ mice is not as obvious as that in liver. The reduced
levels of p53 provide an important molecular mechanism
contributing to the increased tumorigenesis in BECN1+/mice.
To further characterize the effect of spautin-1 on p53, we
examined the effect of spautin-1 on the cytoplasmic and the
nuclear levels of p53 and found that the treatment of spautin-1
can reduce both nuclear and cytoplasmic p53 (Figure S7C).
Furthermore, we found that the effects of spautin on the levels
of Vps34 complexes and autophagy could still be observed in
SKOV-3 ovarian cancer cell line which is null for p53 (Figure S7D).
These results are consistent with the target of spautin-1 being
upstream and independent of p53.
Taken together, our data suggest a model of regulatory rela-
tionship between class III PI3 kinase and p53 via protein interac-
tion and deuqibuitination and the mechanism by which the
Figure 6. Regulation of p53 by Vps34 Complexes, USP10 and USP13
(A-E) H4-LC3-GFP cells were transfected with indicated siRNAs for 72 hr and treated with rapamycin (0.25 mM) or spautin-1 (10 mM) for 4 hr. The cell lysates were
analyzed by western blotting using indicated antibodies. Anti-b-tubulin is a loading control.
(F) Heart, lung and liver tissues of newborn BECN1+/+ andBECN1+/mice were isolated and analyzed by western blotting using indicated antibodies. Anti-actin
was used as a loading control.
Also see Figure S7.treatment with spautin-1 leads to the reduced levels of Vps34
complexes and p53 (Figure 7).
DISCUSSION
In this study, we describe a potent small molecule inhibitor of
autophagy, named spautin-1, that targets the deubiquitination
activity of USP10 and USP13. Using spautin-1 as a tool, we
demonstrate that the ubiquitination and degradation of Vps34
complexes are regulated by two ubiquitin-specific peptidases,
USP10 and USP13. Inhibiting deubiquitination of Vps34
complexes by spautin-1 leads to increased ubiquitination and
degradation of class III PI3 kinase complexes through the pro-
teasomal pathway. Furthermore, our study demonstrates a
physiological mechanism for regulating the class III PI3 kinase
via protein deubiquitination. Since class III PI3 kinase plays an
important role in regulating multiple intracellular vesicular traf-
ficking events including autophagy and endocytosis, the ability
of USP10 and USP13 to regulate the stability of Vps34
complexes provides a molecular mechanism for ubiquitinationand proteasomal degradation to control intracellular vesicular
trafficking. Unlike that of class I and class II PI3 kinases which
need to be activated through receptor signaling, the activity of
class III PI3 kinase is believed to be constitutive (Lindmo and
Stenmark, 2006). Thus, regulating the protein levels of class III
PI3 kinase might provide an important mechanism for controlling
the constitutively active class III PI3 kinase and intracellular
levels of PtdIns3P. Our recent genome-wide siRNA screen on
autophagy demonstrated a prominent role of class III PI3 kinase
in regulating autophagy (Lipinski et al., 2010). It will be interesting
in future to examine if regulating deubiquitination and ubiq-
uitination of Vps34 complexes provides a general mechanism
for controlling the constitutively active class III PI3 kinase
activities under different physiological conditions. Consistent
with the regulation of this deubiquitination mechanism, we found
that the effect of spautin-1 on the levels of Vps34 complexes
are dramatically enhanced in Bcap-37 cells under glucose-free
condition, suggesting that the deubiquitination of Vps34
complexes may be under the control of nutritional availability.
Thus, inhibiting the deubiquitination of Vps34 complexes mightCell 147, 223–234, September 30, 2011 ª2011 Elsevier Inc. 231
Figure 7. A Model: USP10 and USP13 Mediate the Deubiquitination of Vps34 Complexes and p53
(A) In cells treated with spautin-1, USP10 and USP13 are inhibited which leads to increased ubiquitination and degradation of Beclin1 in Vps34 complexes
and p53.
(B) USP13 interacts with Beclin1 in Vps34 complexes which provides a mechanism for Vps34 complexes to regulate the deubiquitination activity of USP13.
USP13 also mediates the deubiquitination of USP10 which explains why knockdown of USP13 also leads to increased degradation of USP10. On the other hand,
knockdown of USP10 leads to the loss of Vps34 complexes which might in turn destabilizes USP13.provide a strategy for developing autophagy inhibitors as an anti-
cancer therapy.
USPs are cysteine proteases containing conserved regions in
their amino acid sequence surrounding theCys, His and Asp/Asn
residues that form the catalytic triad. From the structural studies
of a number of USP family members, it has been noted that the
USP catalytic domains are often not appropriately aligned
without binding to their substrates (Komander, 2010). That is,
the catalytic Cys in USP7 shifts from catalytically inactive posi-
tion to an active position where it interacts with the catalytic
His only when binding to ubiquitin. On the other hand, although
the catalytic machineries of USP14 and USP8 are properly
aligned for catalysis in the absence of ubiquitin, the ubiquitin
binding sites are blocked by the ubiquitin-binding surface loops
(Hu et al., 2005). In addition, the Fingers domain of USP8, which
is important for binding to ubiquitin, folds inward which blocks
the ubiquitin binding site when not interacting with its substrates.
Although no structural information for USP13 and USP10 is
currently available, the enhanced DUB activity when USP13
interacts with USP10 or when they interact with Beclin1 suggest
that the interaction of USP13 and USP10 with each other or with
their substrates can lead to changes in their conformation which
may be critical for the catalytic activities. This provides a possible
model and mechanism for the close interactive regulatory rela-
tionship between USP13/USP10 with Vps34 complexes to
explain why knockdown of USP13/USP10 or Vps34 complexes
lead to reduced levels of the others.
We demonstrate that USP10 and USP13 can both mediate the
deubiquitination of Beclin1. Since the stabilities of the core
components of Vps34 complexes are codependent upon each232 Cell 147, 223–234, September 30, 2011 ª2011 Elsevier Inc.other (Itakura et al., 2008), regulating deubiquitination of Beclin1
may be sufficient to control the levels of whole complex. On the
other hand, our study also demonstrates that Vps34 complexes
can regulate their own levels by a feedback control of USP13.
Since the interaction of USP13 and Beclin1 is detectable by
coimmunoprecipitation, we propose that Beclin1 may have
close interaction with USP13. On the other hand, the interaction
of Beclin1 and USP10 is consistent with that of enzyme/
substrate which is expected to be weak and transient in nature.
Most DUBs with resolved structures show that the enzymes
are in an unproductive conformation before binding to the
substrates. These inactive states might result from the blocking
of the active site by loops or a misalignment of catalytic triads.
Thus, binding to Beclin1 may trigger a major change in the
conformation of USP13 to allow catalysis.
Our study demonstrates that class III PI3 kinase is an impor-
tant tumor suppressor. The role of beclin1 as a haploid-insuffi-
cient tumor suppressor is well-established; however, it has
been unclear how might a reduction in beclin1 expression can
have such a dramatic impact on genomic instability and tumor-
igenesis (Karantza-Wadsworth et al., 2007). Our study demon-
strates that a reduction of beclin1 expression leads to a reduced
p53 level by increasing its ubiquitination, providing an important
molecular mechanism contributing to the role of beclin1 as
a haploid-insufficient tumor suppressor that is frequently mono-
allelically lost in human breast, ovarian, and prostate cancers
(Liang et al., 1999; Qu et al., 2003; Yue et al., 2003).
Recently, using mutant mice with tissue-specific Atg5 or Atg7
deficiency, Takamura et al. showed that multiple benign tumors
developed from autophagy deficient liver, but not in other tissues
(Takamura et al., 2011). Thus, it is unlikely that increased rate of
tumorigenesis inBECN1+/mice is due to autophagy deficiency
as assumed originally. Since Beclin1 has been shown to interact
with Bcl-2, it has also been proposed that decreased levels of
Beclin1 in BECN1+/ cells may promote the activity of Bcl-2
to increase cell survival which in turn promotes tumorigenesis
(Pattingre et al., 2005). While our model does not rule out of
a potential contribution of Bcl-2 or autophagy deficiency from
promoting tumorigenesis in BECN1+/mice, the reduced levels
of p53 as a result of reduction in Beclin1 might provide a mecha-
nism to promote genomic instability which in turn leads to tumor-
igenesis. The ability of Beclin1 to regulate the levels of p53
provides a mechanism underlying the observations that monoal-
lelic loss of beclin1 is sufficient to lead to DNA damage and
genomic instability via gene amplification (Karantza-Wadsworth
et al., 2007).
Consistent with the contribution of p53 deficiency to increased
tumorigenesis in beclin1 heterozygous background, the tumor
spectra of TP53+/mice and BECN1+/mice strongly overlap:
the highest frequencies of tumors in both TP53+/ and
BECN1+/ mice are lung carcinoma, hepatoma and lymphoma
(Jacks et al., 1994; Qu et al., 2003). Furthermore, the beclin1
gene is frequently monoallelically deleted in human sporadic
ovarian, prostate and breast cancers similar to that of p53 muta-
tions (http://www-p53.iarc.fr). The similarities in tumor spectra of
BECN1+/ mice and TP53+/ mice suggest that reduced p53
levels play an important role in promoting tumorigenesis in
BECN1+/ mice. Since the stability of the components of
Vps34 complexes are largely codependent upon each other,
reduced expression of other components of Vps34 complexes,
including Vps34, p150, Atg14L and UVRAG, also leads to
reduced levels of p53. Thus, our data suggest that all compo-
nents of Vps34 complexes can regulate the levels of p53.
Curiously, although monoallelic loss of beclin1 is frequently
observed in breast, ovarian and prostate cancers, the loss of
heterozygocity of beclin1 was not commonly observed (Liang
et al., 1999; Qu et al., 2003; Yue et al., 2003). Thus, beclin 1might
not represent a ‘‘conventional’’ tumor suppressor such as Rb
that satisfies the ‘‘Knudson two-hit hypothesis’’ criteria for clas-
sification as a tumor suppressor gene which indicates that it
is necessary to demonstrate loss of both alleles, via either dele-
tion or the presence of inactivating mutations (Knudson, 1971).
Since TP53/mice are viable while BECN1/mice are early
embryonic lethal, Vps34 complexes must provide a wider range
of vital cellular functions than controlling p53 protein levels.
Thus, while a reduction in beclin1 expression might promote
tumorigenesis by reducing the levels of p53, a complete loss of
beclin1 might negatively impact the development of certain
tumors at least as a complete loss of beclin1 leads to early
embryonic lethality (Qu et al., 2003; Yue et al., 2003) and might
be required for cell viability at least for certain cell types. Thus,
unlike ‘‘conventional’’ tumor suppressor, bi-allelic loss of beclin1
may not promote tumorigenesis and may lead to cell death.
Consistent with this possibility, in contrast to that of normal cells,
selected cancer cell lines demonstrate an increased sensitivity
toward spautin-1 under starvation condition, suggesting that
spautin-1 may be used to synergize with selected chemothera-
peutic agents to induce cancer cell death. Spautin-1 mighttherefore provide a potential lead compound for developing
a class of autophagy inhibitors as anticancer therapy.
EXPERIMENTAL PROCEDURES
High-Throughput Image Analysis
Cells were fixed with 4% paraformaldehyde (Sigma) and stained with 3 mg/ml
DAPI (Sigma). Images data were collected with an ArrayScan HCS 4.0 Reader
with a 203 objective (Cellomics ArrayScan VTI) for DAPI-labeled nuclei and
GFP/RFP-tagged intracellular proteins.
Cell Lines and Culture Conditions
293T, MEF, HeLa, and Bcap-37 cells were cultured in DMEM media with 10%
NCS. H4-LC3-GFP, H4-FYVE-RFP and MDCK cells were cultured in DMEM
supplemented with 10% FBS and 1 X Na pyruvate (Invitrogen). Hs578Bst cells
were cultured in Hybri-Care Medium (ATCC), supplemented with 30 ng/ml
mouse EGF and 10% FBS. For starvation experiments, cells were cultured
in DMEM supplemented with 10% serum without Glucose (GIBCO).
Antibodies
Rabbit polyclonal antibody anti-USP10, anti-USP13,anti-UVRAG,anti-Vps34
and anti-p53, were from Abcam. Rabbit polyclonal antibody anti-LC3B and
mouse monoclonal antibody anti-b-tubulin were from sigma. Monoclonal anti-
bodies anti-flag, anti-Myc and anti-HA were from Abmart. Rabbit polyclonal
antibody anti-Beclin1 was from Santa Cruz. Polyclonal antibody anti-Atg14L
was from MBL.
Protein-Lipid Blot Assay
Protein-lipid blot assays were carried out as reported (Dowler et al., 2002; Go-
zani et al., 2003). Briefly, lipids extracted from a 100 mm plate was spotted
onto Hybond C-extra membrane (Amersham) and allowed to dry overnight in
the dark. The membrane was incubated with lipid blocking buffer (1% BSA in
TBST) for 1 hr, washed once in TBST for 30 min, and incubated with protein
buffer (1 mg GST-tagged protein per 1 ml TBST with 1% BSA) overnight at 4C.
Then the membrane was washed again in TBST for four times at 30 min each,
incubated with anti-GST (Sigma) in 1% BSA buffer for 4 hr, washed in TBST
for four changes with 5 min each, incubated with secondary antibody for 1 hr,
and washed in TBST for four changes with 5 min each. All incubations were at
roomtemperatureunlessnotedotherwise. Thesignalswere visualizedwithECL.
In Vitro Deubiquitination Assay
In vitro deubiquitination assay was carried out using a similar protocol as
described in (Yuan et al., 2010). Ubiquitinated Beclin1 was isolated from 293T
cells transfected with expression vectors for HA-UB and FLAG-Beclin1. After
Incubation with proteasome inhibitor MG132 (25 mM) and a pan DUB inhibitor
G5 (25 mM) for 6 hr, ubiquitinated Beclin1 was purified from the cell extracts
with anti-FLAG-affinity column in FLAG-lysis buffer (50 mM Tris-HCl [pH 7.8],
137mM NaCl, 10mM NaF, 1mM EDTA, 1% Triton X-100, 0.2% Sarcosyl, 1mM
DTT, 10% glycerol and fresh proteinase inhibitors). After extensive washing
with the FLAG-lysis buffer, the proteins were eluted with FLAG-peptides
(Sigma). The recombinant Flag-USP10 and USP10CA were expressed in
293T cells and purified using FLAG affinity column and eluted with FLAG-
peptide. For in vitro deubiquitination assay, ubiquitinated Beclin1 protein was
incubated with recombinant USP10 in the deubiquitination buffer (50 mM Tris-
HCl [pH8.0], 50mMNaCl, 1mMEDTA, 10mMDTT, 5%glycerol) for 2 hr at 37C.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and one table and can be found with this article online at doi:10.1016/
j.cell.2011.08.037.
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